v3 Template
P

Phrontline Biopharma

Biopharmaceuticals/Oncology
Founded
--
Employees
--
Total Funding
$60.0M
Funding Rounds
1
Last Funding
2025-11-24

About Phrontline Biopharma

Phrontline Biopharma is a biopharmaceutical company dedicated to developing innovative antibody-drug conjugates (ADCs) to address unmet medical needs in oncology. They aim to become a leading global entity by delivering next-generation frontline cancer therapies through scientific innovation and precision-engineered dual-targeting antibodies.

Products & Services

TJ101:Bispecific ADC targeting EGFR x B7H3 for NSCLC, HNSCC, and other indications.
TJ106:Bispecific dual payload ADC targeting HER2 x HER2 for breast cancer (pan-Her2).
SynTume Platform:A proprietary technology platform for developing innovative ADCs.
2by2 ADC:A dual-payload ADC platform designed to overcome drug resistance and extend treatment response.

Specialties

Antibody-Drug Conjugates (ADCs) Bispecific Dual Payload ADCs Dual-Targeting Antibodies Dual-Payload Platforms Cancer Therapies

Funding History

Debug: View Raw Funding Data
# Type Amount Fields Date Fields Investors
1 RT: Pre-A+
T: -
FT: Pre-A+ 		A: 60000000
MR: -
FA: $60 million
FAN: 60000000 		D: 2025-11-24
FD: 2025-11-24 		10 investors
Pre-A+ Latest
2025-11-24
$60.0M
10 investors (Pro only)

Growth Metrics

+45%
Employee Growth
YoY
3.2x
Funding Growth
Last Round
12
Markets
Operating
10K+
Customers
Active

View 3 more growth metrics with Pro

Unlock All Metrics
Mock Up

Team & Leadership

No team data available

Team information is not yet available for this company

Recent News

Phrontline Biopharma Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Read more →

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Read more →

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Read more →

View 2 more news articles with Pro

Unlock Full News Feed
Mock Up

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised

Mock Up

Company Details

Industries
Biopharmaceuticals/Oncology

Technology Stack

Discover the backend, frontend, and infrastructure technologies powering this company's products.

Upgrade to Pro